How Manufacturing Differences Affect GLP-1 Drug Quality and Safety | Research

The takeaway

Manufacturing process differences between originator and follow-on GLP-1 analog drugs create distinct impurity profiles that could affect immunogenicity and clinical outcomes.

5 suppliers
Follow-on liraglutide manufacturers showed distinct impurity profiles compared to originator

What the researchers found

Manufacturing differences between originator and follow-on GLP-1 analogs produce distinct impurity profiles with potential immunogenicity implications, requiring clinical evaluation.

Why it matters

As GLP-1 agonists become blockbuster drugs, follow-on versions are entering the market. Manufacturing differences can meaningfully affect quality in ways requiring safety evaluation.

The numbers in context

5 alternative suppliers vs originator; distinct impurity profiles; trace metals ↑ HMW formation; semaglutide immunogenicity < liraglutide in SUSTAIN

How the study worked

Analytical comparison of drug substances from multiple suppliers, in silico T cell epitope prediction, and clinical immunogenicity data from SUSTAIN trials.

Who was studied

Analytical comparison of products from 6 manufacturers

What this study cannot tell us

In silico immunogenicity predictions require clinical confirmation. Not all suppliers may represent actual marketed products.

How to read the evidence

Rigorous analytical study combining chemistry, computational prediction, and clinical immunogenicity data.

When this study was published

Published in 2020. Increasingly relevant as GLP-1 biosimilars enter global markets.

The bigger picture

Critical for regulators and clinicians as the GLP-1 drug market expands — manufacturing quality isn't just a technical detail, it can affect patient safety.

Questions still open

Should follow-on GLP-1 analogs require full clinical trials?
Can improved manufacturing eliminate immunogenic impurities?
Do impurity differences translate to clinical outcome differences?

Common questions

Are generic GLP-1 drugs as good as brand-name?

This study found follow-on versions of liraglutide had different impurity profiles than the original, raising immunogenicity concerns. While they contain the same active ingredient, manufacturing differences can affect quality.

Why does manufacturing matter for peptide drugs?

Peptide drugs are complex molecules sensitive to manufacturing conditions. Differences in production can introduce impurities that may trigger immune reactions or reduce stability, potentially affecting safety and effectiveness.

Read the original research

Influence of Production Process and Scale on Quality of Polypeptide Drugs: a Case Study on GLP-1 Analogs.

Pharmaceutical research, 37(7), 120

View on PubMed ↗Publisher’s paper ↗

Citation

Staby, Arne; Steensgaard, Dorte Bjerre; Haselmann, Kim F; Marino, Jesper Søndergaard; Bartholdy, Christina; Videbæk, Nicoline; Schelde, Ole; Bosch-Traberg, Heidrun; Spang, Lotte Touborg; Asgreen, Désirée J. (2020). Influence of Production Process and Scale on Quality of Polypeptide Drugs: a Case Study on GLP-1 Analogs.. Pharmaceutical research, 37(7), 120. https://doi.org/10.1007/s11095-020-02817-9